146 related articles for article (PubMed ID: 34167970)
1. SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy.
Chew SM; Lucas M; Brady M; Kelly CM
BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34167970
[TBL] [Abstract][Full Text] [Related]
2. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
5. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
6. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
8. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
10. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
11. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
12. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
13. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
15. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
17. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
18. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]